Gregory Russotti Sells 5,000 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $3.10, for a total value of $15,500.00. Following the transaction, the insider now owns 297,319 shares in the company, valued at $921,688.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Century Therapeutics Trading Up 6.4 %

Century Therapeutics stock opened at $3.15 on Friday. Century Therapeutics, Inc. has a twelve month low of $1.28 and a twelve month high of $5.51. The stock’s fifty day simple moving average is $4.07 and its 200-day simple moving average is $3.13. The firm has a market capitalization of $204.18 million, a P/E ratio of -1.38 and a beta of 1.33.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.07. Century Therapeutics had a negative return on equity of 54.73% and a negative net margin of 6,115.12%. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $1.69 million. Sell-side analysts predict that Century Therapeutics, Inc. will post -1.94 earnings per share for the current year.

Wall Street Analyst Weigh In

IPSC has been the topic of several recent research reports. Canaccord Genuity Group boosted their target price on Century Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Piper Sandler restated an “overweight” rating and set a $9.00 target price (down from $10.00) on shares of Century Therapeutics in a report on Friday, April 12th. Finally, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Century Therapeutics in a report on Friday, March 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.60.

Hedge Funds Weigh In On Century Therapeutics

Large investors have recently bought and sold shares of the business. Abel Hall LLC purchased a new position in Century Therapeutics in the fourth quarter valued at $33,000. Federated Hermes Inc. increased its holdings in Century Therapeutics by 0.4% in the fourth quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock valued at $2,053,000 after buying an additional 2,500 shares during the last quarter. Finally, Avidity Partners Management LP increased its holdings in Century Therapeutics by 23.4% in the fourth quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after buying an additional 256,500 shares during the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.